MGMT promoter methylation status in anaplastic meningiomas.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

1. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.Acta neuropathologica · 2017
   Article
2. Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme.European radiology · 2013
   Article
3. Lack of MGMT promoter hypermethylation in hemangiopericytomas of the central nervous system.Journal of neuro-oncology · 2012
   Article
4. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.Journal of neuro-oncology · 2012
   Article
5. Molecular diagnostics of gliomas: state of the art.Acta neuropathologica · 2010
   Review
6. Pyrosequencing Analysis ofCancer genomics & proteomics
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors at 4 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as